- Home
- ANAB vs GHM Comparison
ANAB vs GHM Comparison
Compare ANAB & GHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- GHM
- Stock Information
- Founded
- ANAB 2005
- GHM 1936
- Country
- ANAB United States
- GHM United States
- Employees
- ANAB N/A
- GHM N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- GHM Industrial Machinery/Components
- Sector
- ANAB Health Care
- GHM Industrials
- Exchange
- ANAB Nasdaq
- GHM Nasdaq
- Market Cap
- ANAB 621.1M
- GHM 577.9M
- IPO Year
- ANAB 2017
- GHM N/A
- Fundamental
- Price
- ANAB $26.94
- GHM $54.93
- Analyst Decision
- ANAB Buy
- GHM Strong Buy
- Analyst Count
- ANAB 10
- GHM 2
- Target Price
- ANAB $49.00
- GHM $60.00
- AVG Volume (30 Days)
- ANAB 526.3K
- GHM 117.3K
- Earning Date
- ANAB 08-08-2025
- GHM 08-05-2025
- Dividend Yield
- ANAB N/A
- GHM N/A
- EPS Growth
- ANAB N/A
- GHM 164.29
- EPS
- ANAB N/A
- GHM 1.11
- Revenue
- ANAB $111,872,000.00
- GHM $209,896,000.00
- Revenue This Year
- ANAB N/A
- GHM $13.19
- Revenue Next Year
- ANAB $24.39
- GHM $8.81
- P/E Ratio
- ANAB N/A
- GHM $49.48
- Revenue Growth
- ANAB 387.20
- GHM 13.13
- 52 Week Low
- ANAB $12.21
- GHM $24.78
- 52 Week High
- ANAB $41.31
- GHM $54.93
- Technical
- Relative Strength Index (RSI)
- ANAB 66.30
- GHM 72.30
- Support Level
- ANAB $25.48
- GHM $51.08
- Resistance Level
- ANAB $28.50
- GHM $54.65
- Average True Range (ATR)
- ANAB 1.26
- GHM 1.54
- MACD
- ANAB 0.02
- GHM -0.05
- Stochastic Oscillator
- ANAB 70.23
- GHM 100.00
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About GHM Graham Corporation
Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.